[Header as appropriate for mail or email letter]

Dear [patient name]:

Our records here at [provider/network office name] indicate you may be due for a colorectal cancer screening.

Colorectal cancer is the second leading cause of cancer deaths in the United States, taking the lives of about 53,000 Americans each year—more than breast cancer (~44,000/year) or prostate cancer (~35,000/year).1

The good news is colorectal cancer may be preventable through screening and is highly treatable when detected in early stages.1 A variety of colorectal cancer screening options, including noninvasive tests, may be fully covered as preventive benefits by your health insurance plan.

As your healthcare provider, we can help explain the screening options available to you and answer your questions. One noninvasive option is Cologuard®, a stool-based test for patients 45 and older at average risk that detects blood and altered DNA associated with colorectal cancer. The test kit is shipped to your home and can be picked up via UPS®, without ever leaving your house. Exact Sciences Laboratories provides results to your office within a few weeks.

**Indications and Important Risk Information**  
Cologuard is intended to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use if you have had adenomas, have inflammatory bowel disease and certain hereditary syndromes, or a personal or family history of colorectal cancer. Cologuard is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. Cologuard performance in repeat testing has not been evaluated.

The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for diagnostic colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again. False positives and false negative results can occur. In a clinical study, 13% of people without cancer received a positive result (false positive) and 8% of people with cancer received a negative result (false negative). Rx only.

Please contact us if you would like to be screened for colorectal cancer using Cologuard, an at home, easy-to-use, noninvasive colon cancer screening test.

[Provider contact information]


[Sign off]

**References:**

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*. 2022;72:7-33.

Cologuard is a registered trademark of Exact Sciences Corporation. All other trademarks are the properties of their respective owners.

©2022 Exact Sciences Corporation. All rights reserved. US.CG.03016-March 2022

<INSERT SYSTEM LOGO>